Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns naming John Newham .
Filed returns
20
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Pfizer | Health | Discussion on the EU Biotech Act, access to medicines, innovation, and Ireland's life sciences policy environment, including opportunities to strengthen research, development, manufacturing, and the competitiveness of… (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2026 | Novartis Ireland Limited | Health | Life Science Strategy (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2026 | Vulcan Consulting Limited | Health | Rare Disease Policy (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2026 | Vulcan Consulting Limited | Health | Strategic Operations in Ireland and Healthcare Priorities (Public policy or programme) | 13 | On lobbying.ie |
| May–Aug 2026 | Janssen Sciences Ireland UC | Health | Engagement with the Departments of Health and Enterprise regarding the national life science strategy (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2026 | Irish Pharmaceutical Healthcare Association | Health | Industry position on a National Life Sciences Strategy (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Takeda Products Ireland | Health | National Life Science Strategy engagements (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Health | Ireland’s National Life Sciences Strategy (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Health | Ireland's medicine reimbursement system and access to new medicine (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 16 | On lobbying.ie |
| Jan–Apr 2026 | Vulcan Consulting Limited | Health | EU Pharmaceutical Policy (Legislation) | 3 | On lobbying.ie |
| Sep–Dec 2025 | Irish Pharmaceutical Healthcare Association | Health | New framework Agreement on the Pricing and Supply of Medicines. (Matters involving public funds) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Irish Pharmaceutical Healthcare Association | Health | New framework Agreement on the Pricing and Supply of Medicines. (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Irish Pharmaceutical Healthcare Association | Health | US-EU Trade Tariffs (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2025 | Irish Pharmaceutical Healthcare Association | Health | A National Life Sciences Strategy (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2025 | Irish Pharmaceutical Healthcare Association | Health | Future Framework Agreement (Legislation) | 6 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on access to medicines in EU smaller countries/markets and intellectual property rights. (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on intellectual property rights. (ii) Proposed Life Sciences Strategy. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | Issues concerning the timely reimbursement of medicines in Ireland. (Public policy or programme) | 12 | On lobbying.ie |
| May–Aug 2024 | AstraZeneca Pharmaceuticals (Ireland) DAC | Health | Meeting to discuss the EU Pharmaceutical legislation (Public policy or programme) | 1 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 20 | 100.0% |